[HTML][HTML] Anemia in myelofibrosis: current and emerging treatment options
F Passamonti, CN Harrison, RA Mesa… - Critical Reviews in …, 2022 - Elsevier
Myelofibrosis (MF) is a clonal hematologic malignancy with progressive bone marrow
fibrosis. Clinical manifestations of MF include splenomegaly, constitutional symptoms, and …
fibrosis. Clinical manifestations of MF include splenomegaly, constitutional symptoms, and …
Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology
AT Gerds, J Gotlib, H Ali, P Bose, A Dunbar… - Journal of the National …, 2022 - jnccn.org
The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …
[HTML][HTML] A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in …
M Wasserstein, R Lachmann, C Hollak… - Genetics in …, 2022 - Elsevier
Purpose This trial aimed to assess the efficacy and safety of olipudase alfa enzyme
replacement therapy for non–central nervous system manifestations of acid …
replacement therapy for non–central nervous system manifestations of acid …
Myeloproliferative neoplasms in adolescents and young adults
R Amerikanou, J Lambert, S Alimam - Best Practice & Research Clinical …, 2022 - Elsevier
Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders commonly diagnosed in
the seventh decade of life. With increasing access to blood surveillance, the number of …
the seventh decade of life. With increasing access to blood surveillance, the number of …
[HTML][HTML] Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S …
Mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR),
including L858R/T790M double and L858R/T790M/C797S triple mutations, are major …
including L858R/T790M double and L858R/T790M/C797S triple mutations, are major …
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study
J Mascarenhas, F Passamonti, K Burbury… - Blood …, 2022 - ashpublications.org
Idasanutlin, an MDM2 antagonist, showed clinical activity and a rapid reduction in JAK2
V617F allele burden in patients with polycythemia vera (PV) in a phase 1 study. This open …
V617F allele burden in patients with polycythemia vera (PV) in a phase 1 study. This open …
Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa …
GL Mazza, C Mead-Harvey, J Mascarenhas… - The Lancet …, 2022 - thelancet.com
Background Patients with essential thrombocythaemia or polycythaemia vera have several
symptoms that can worsen their quality of life. We aimed to assess how symptom burden …
symptoms that can worsen their quality of life. We aimed to assess how symptom burden …
Association between cancer-related fatigue and falls in patients with myeloproliferative neoplasms: results of a multicenter cross-sectional survey from the east …
Objective: This study retrospectively examined the association between cancer-related
fatigue (CrF) and the number of falls during the last 12 months in patients with …
fatigue (CrF) and the number of falls during the last 12 months in patients with …
Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: results of a pilot study
S Qu, Z Xu, T Qin, B Li, L Pan, J Chen… - Hematological …, 2022 - Wiley Online Library
Ruxolitinib is a safe and effective therapy of myeloproliferative neoplasm‐associated (MPN)
myelofibrosis. However, often there are dose reductions and/or therapy interruptions …
myelofibrosis. However, often there are dose reductions and/or therapy interruptions …
Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth
J Gotlib - Blood, The Journal of the American Society of …, 2022 - ashpublications.org
Polycythemia vera (PV) is a Philadelphia chromosome-negative myeloproliferative
neoplasm driven by the JAK2 V617F (or rarely exon 12) mutation. Its natural history can …
neoplasm driven by the JAK2 V617F (or rarely exon 12) mutation. Its natural history can …